[5] Topical GHK-Cu is generally considered well tolerated, yet therapy should be avoided in individuals with a known hypersensitivity to copper peptides or any vehicle component
Because of their potential therapeutic effects, peptides have become a prominent focus in medical science and health care
For people with a genuine deficiency, yes, the evidence is solid
All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB)
Additionally, researchers have posited that the peptide may affect the activity of lipases, a group of enzymes that prevent the return of fat to adipose tissues
Because it didn't clearly work, it was not approved as a weight-loss drug, and development stalled